New JDD Research Paper Finds Few Atopic Dermatitis Topicals Treat Full Spectrum of Disease; Alphyn’s Zabalafin Hydrogel Candidate Cited as Potential Multi-Target Option
New JDD Research Paper Finds Few Atopic Dermatitis Topicals Treat Full Spectrum of Disease; Alphyn’s Zabalafin Hydrogel Candidate Cited as Potential Multi-Target Option NEWS PROVIDED BY Alphyn Biologics Nov 09, 2026, 07:30 ET Leading dermatologist authors note emerging evidence for Zabalafin’s anti-inflammatory, anti-pruritic, anti-microbial and anti-xerotic effects ANNAPOLIS, Md., Nov. 9, 2026 /PRNewswire/ — /PRNewswire/…


